Search results
Results from the WOW.Com Content Network
Attention deficit hyperactivity disorder management options are evidence-based practices with established treatment efficacy for ADHD.Approaches that have been evaluated in the management of ADHD symptoms include FDA-approved pharmacologic treatment and other pharmaceutical agents, psychological or behavioral approaches, combined pharmacological and behavioral approaches, cognitive training ...
This is a list of investigational attention deficit hyperactivity disorder drugs, or drugs that are currently under development for clinical use in the treatment of attention deficit hyperactivity disorder (ADHD) but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in ...
Hydrochlorothiazide, sold under the brand name Hydrodiuril among others, is a diuretic medication used to treat hypertension and swelling due to fluid build-up. [4] Other uses include treating diabetes insipidus and renal tubular acidosis and to decrease the risk of kidney stones in those with a high calcium level in the urine . [ 4 ]
Viloxazine is indicated to treat attention deficit hyperactivity disorder (ADHD) in children age 6 to 12 years, adolescents age 13 to 17 years, and adults. [1]Analyses of clinical trial data suggest that viloxazine produces moderate reductions in symptoms; it is about as effective as atomoxetine and methylphenidate but with fewer side effects.
Concerta (methylphenidate) – an extended release form of methylphenidate Contrave ( naltrexone/bupropion ) – a combination drug used in the treatment of mood and psychotic disorders. It is also approved for weight loss in those that are either obese or overweight with some weight-related illnesses
The book had a sequel Contemporary Guide to Adult ADHD (2009), about adults with ADHD. It outlines clinical guidelines and recommended pharmacotherapies for the treatment of adult men and women. [citation needed] The author is a physician based in Rochester Hills, Michigan.
Improvements in ADHD symptoms in children were significantly greater for dexmethylphenidate XR versus placebo. [6] It also showed greater efficacy than osmotic controlled-release oral delivery system ( OROS ) methylphenidate over the first half of the laboratory classroom day but assessments late in the day favoured OROS methylphenidate.
In children, ADHD occurs with other disorders about two-thirds of the time. [73] Other neurodevelopmental conditions are common comorbidities. Autism spectrum disorder (ASD), co-occurring at a rate of 21% in those with ADHD, affects social skills, ability to communicate, behaviour, and interests.